Since the approval of rituximab in 1997. monoclonal antibodies (mAbs) have become an increasingly important component of therapeutic regimens in oncology. The success of mAbs as a therapeutic class is a result of great strides that have been made in molecular biology and in biotechnology over the past several decades. Currently. https://yeswellneses.shop/product-category/vitamins-for-kids/